Osamah Saeedi, MD
Glaucoma Specialist · Baltimore, MDNPI 1285895508
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Topcon Healthcare, Inc. at 58.5% of the total. Reporting peaked in 2022 at $5,649 and has fallen 99.4% since, to $34 in 2025.
Across 21 payments — averaging $458.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Topcon Healthcare, Inc.$6K
- Heidelberg Engineering, Inc.$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
- Glaukos Corporation$158
- AbbVie$120
- NEW World Medical,inc.$54
- plus $34 from 1 others
Across 5 payments — averaging $13,726 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aerie Pharmaceuticals, Inc.$37K
- Alcon Research LLC$31K
What the payments were for
- Consulting fees$3,00031%
- Speaking & faculty fees$3,60037%
- Travel & lodging$2,49826%
- Food & beverage$5386%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Topcon Healthcare, Inc. | 12 | $5,635 |
| Heidelberg Engineering, Inc. | 2 | $2,400 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $1,235 |
| Glaukos Corporation | 1 | $158 |
| AbbVie | 1 | $120 |
| NEW World Medical,inc. | 2 | $54 |
| Tarsus Pharmaceuticals, Inc. | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Spectralis$2,400
- PROLENSA$1,200
- LOTEMAX$1,200
- ENVISTA$1,200
- VICTUS$1,200
- STELLARIS$1,200
- iAccess Precision Blade$158
How this compares
Too few glaucoma specialist providers in Marylandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 110 | $60,325 |
| LumiganBimatoprost | 124 | $57,453 |
| Brimonidine Tartrate | 220 | $17,239 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 42 | $15,076 |
| CombiganBrimonidine Tartrate/Timolol | 36 | $13,906 |
| RocklatanNetarsudil Mesylat/Latanoprost | 34 | $13,786 |
| Travoprost | 56 | $8,103 |
| VyzultaLatanoprostene Bunod | 15 | $6,728 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 33 | $5,633 |
| Latanoprost | 334 | $4,270 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 220 | $4,009 |
| Brinzolamide | 14 | $3,229 |
| Fluorometholone | 11 | $2,900 |
| Prednisolone Acetate | 50 | $2,283 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 21 | $2,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $120 | $71,359160 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Marylandon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Baltimore
- Katherine FallanoBaltimore$2K
- Teresa HoranBaltimore$2K
- Elyse McGlumphyBaltimore$2K
- Karun AroraBaltimore$1K
- Heran GebreyesusBaltimore$179
- Eva DevienceBaltimore$94
- Jonathan KatzLutherville$10K
- Alanna JamesBowie$5K
- Heather NestiAnnapolis$5K
- Russell HuangBethesda$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.